Drug · CHEMBL1237
LISINOPRIL ANHYDROUS
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. LISINOPRIL ANHYDROUS. Drugs and targets, record CHEMBL1237. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1237
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ACE | Angiotensin-converting enzyme | Angiotensin-converting enzyme inhibitor | INHIBITOR | https://conductscience.org/library/genes/1636 |
Source ChEMBL
Diseases16
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| hypertensive disorder | Phase 3 | ClinicalTrials.gov | 8 | 8 | https://conductscience.org/library/drugs?q=MONDO_0005044 |
| Cognitive impairment | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0100543 |
| autosomal dominant polycystic kidney disease | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0004691 |
| left ventricular hypertrophy | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0003896 |
| stroke disorder | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005098 |
| Moderate albuminuria | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012594 |
| Reduced left ventricular ejection fraction | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012664 |
| acute coronary syndrome | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005542 |
| chronic kidney disease | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005300 |
| coronary artery disorder | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005010 |
1 to 10 of 16Source Open Targets
See all 16 diseasesTrials40
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00555217 | VA NEPHRON-D: Diabetes iN Nephropathy Study | Phase 3 | 1,448 | 2015-05-29 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT00347360 | The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial | Phase 3 | 654 | 2009-11-09 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT00283686 | HALT Progression of Polycystic Kidney Disease Study A | Phase 3 | 558 | 2015-02-27 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT01885559 | HALT Progression of Polycystic Kidney Disease Study B | Phase 3 | 486 | 2015-03-10 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT01009918 | Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab | Phase 2 | 468 | 2021-03-30 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT00108082 | The CLEVER Study - Coreg And Left Ventricular Mass Regression | Phase 3 | 287 | 2009-11-09 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT00391846 | Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone | Phase 4 | 252 | 2012-06-18 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT00582114 | Hypertension in Hemodialysis Patients (Aim 3) | Phase 3 | 200 | 2016-01-18 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT01837069 | Risk Factor Control Before Orthopedic Surgery | Phase 4 | 198 | 2020-07-27 | lisinopril | The name of another form of it | ClinicalTrials.gov |
| NCT01984164 | CAndesartan vs LIsinopril Effects on the BRain | Phase 2 | 176 | 2021-02-21 | lisinopril | The name of another form of it | ClinicalTrials.gov |
1 to 10 of 40
See all 40 trialsComparisons in its trials23
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Combination of ARB and ACEI vs Monotherapy ARB: A Composite Endpoint of Reduction in Estimated GFR of 30ml/Min/1.73m*m in Individuals w/a Baseline Estimated GFR >= 60 ml/Min/1.73m*m, Reduction in Estimated GFR >50% in Individuals w/ Baseline Estimated GFR <60ml/Min/1.73m*m; ESRD or Death | 132 of 724 | 152 of 724 | 1,448 | NCT00555217 | Trial comparisons |
Combination of ARB and ACEI vs Monotherapy ARB: A Renal Composite Endpoint, Defined as; Reduction in Estimated GFR of >50% (for Individuals With Baseline GFR <60) or Reduction in GFR of >30 (for Individuals With Baseline GFR >= GFR 60) or ESRD. | 77 of 724 | 101 of 724 | 1,448 | NCT00555217 | Trial comparisons |
| Combination of ARB and ACEI vs Monotherapy ARB: serious adverse events | 416 of 724 | 380 of 724 | 1,448 | NCT00555217 | Trial comparisons |
| ACE-I + Placebo vs ACE-I + ARB: serious adverse events | 88 of 242 | 88 of 244 | 486 | NCT01885559 | Trial comparisons |
| ACE-I + Placebo vs ACE-I + ARB: Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death. | 116 of 242 | 115 of 243 | 485 | NCT01885559 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: Discontinuations | 8 of 127 | 6 of 125 | 252 | NCT00391846 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: serious adverse events | 46 of 127 | 41 of 125 | 252 | NCT00391846 | Trial comparisons |
| Guided by NT-proBNP vs Not Guided by NT-proBNP: Number of CV Deaths | 4 of 123 | 5 of 123 | 246 | NCT00391846 | Trial comparisons |
| Atenolol vs Lisinopril: serious adverse events | 58 of 100 | 70 of 100 | 200 | NCT00582114 | Trial comparisons |
| Treatment vs Control: Number of Partipants That Experienced Death, Myocardial Infarction, Stroke, Transient Ischemic Attack, Myocardial Necrosis, or Venous Thromboembolism | 10 of 103 | 2 of 95 | 198 | NCT01837069 | Trial comparisons |
1 to 10 of 23
See all 23 comparisons in its trialsPapers from its trials76
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials8
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Digit Span Test | 2 | 1 | ConductCognition |
| Trail Making Test B | 2 | 2 | ConductCognition |
| Verbal Learning | 2 | 1 | ConductCognition |
| Category Fluency | 1 | 1 | ConductCognition |
| Eriksen Flanker Task | 1 | 1 | ConductCognition |
| 1-Back Task | 1 | 1 | ConductCognition |
| Picture Naming Test | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1237
GET https://conductscience.org/api/drugs/v1/CHEMBL1237/trials?page=2